Skip to content

Observational study on the effect of interleukin-39 on the severity and prognosis of acute pancreatitis

Observational study on the effect of interleukin-39 on the severity and prognosis of acute pancreatitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040421
Enrollment
Unknown
Registered
2020-11-28
Start date
2020-11-20
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis

Interventions

Case series:No

Sponsors

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 90 years old; 2. If they are women in childbearing period, they should contraception at least one month before screening, and promise to take contraception during the whole study period and continue to the specified time after the end of the study; 3. Within 72 hours after onset of the disease; 4. The diagnosis of acute pancreatitis was consistent with the following 2 items; (1) Abdominal pain: acute attack of persistent, severe abdominal pain, often radiated to the back; (2) Serum lipase activity (or amylase) was at least 3 times higher than the upper limit of normal value; (3) CT or MRI showed the characteristic changes of acute pancreatitis. 5. All the patients signed the informed consent of the study.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. More than 72 hours of onset; 3. Severe chronic failure of heart, liver, lung, kidney and blood system existed before admission; 4. Cancer without cure; 5. Autoimmune disease or immunosuppression (previous solid organ or bone marrow transplantation, AIDS, long-term use of immunosuppressants or hormones, etc.); 6. Use of other trial drugs within the time frame of this study; 7. Patients and their families refused to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Severity of acute pancreatitis;Interleukin 39;

Secondary

MeasureTime frame
Prognosis;Interleukin 2 receptor;Interleukin 6;Interleukin 8;Interleukin 10;Interleukin 1ß;Tumor necrosis factor-alpha;SOFA score;triglyceride;Local complications;BISAP score;Marshall score;Balthazar CT socre;Serum amylase;APACH II score;Blood cell analysis;Blood gas analysis;Liver function index;Renal function index;temperature;heart rate;blood pressure;Coagulation function index;C-reactive protein;Procalcitonin;NT-proBNP;Myocardial protein;Immune function index;Humoral immunity index;days in hospital;Abdominal CT scan;micro-organism cultur;

Countries

China

Contacts

Public ContactEnqiang Mao

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

maoeq@yeah.net+86 13501747906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026